Shaheen Wirk - 15 Apr 2025 Form 4/A - Amendment Insider Report for Tvardi Therapeutics, Inc. (TVRD)

Role
Director
Signature
/s/ Dan Conn, Attorney- in-Fact
Issuer symbol
TVRD
Transactions as of
15 Apr 2025
Net transactions value
$0
Form type
4/A - Amendment
Filing time
02 May 2025, 18:12:20 UTC
Date Of Original Report
17 Apr 2025
Previous filing
06 Jan 2025
Next filing
21 Apr 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Wirk Shaheen Director C/O TVARDI THERAPEUTICS, INC., 3 SUGAR CREEK CTR BLVD, STE 525, SUGAR LAND /s/ Dan Conn, Attorney- in-Fact 02 May 2025 0002050227

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TVRD Common Stock Award +176,030 176,030 15 Apr 2025 Palkon Holdings, LLC F1, F2, F3, F4
transaction TVRD Common Stock Award +263,164 263,164 15 Apr 2025 Palkon TT Holdings, LLC F1, F2, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The initial Form 4 inadvertently listed an incorrect transaction code.
F2 Under the terms of the Merger Agreement, on April 15, 2025, Merger Sub merged with and into Legacy Tvardi (the "Merger"), with Legacy Tvardi surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of Legacy Tvardi stock was converted into the right to receive 0.1341 of shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc.
F3 Received in exchange for 1,312,508 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement.
F4 The Reporting Person is a Managing Manager of the Palkon Holdings LLC and Palkon TT Holdings LLC (the "Palkon entities"). The Reporting Person may be deemed to share the power to direct the disposition and vote of the shares held by the Palkon entities, but disclaims beneficial ownership, except to any pecuniary interests therein.
F5 Received in exchange for 1,962,199 shares of Series B Preferred Stock of Legacy Tvardi pursuant to Merger Agreement.